Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Dihomo-gamma-linolenic acid (DGLA) is an omega-6 fatty acid that serves as a metabolic intermediate between gamma-linolenic acid (GLA) and arachidonic acid (AA). There is a modest body of scientific literature exploring the potential of DGLA and its precursors (such as GLA) in modulating inflammation and immune responses, which are central to the pathophysiology of many autoimmune disorders. DGLA can be converted to anti-inflammatory prostaglandins, particularly prostaglandin E1 (PGE1), which may help counteract excessive inflammation associated with autoimmune conditions. Some in vitro and animal studies suggest that supplementation with GLA or direct provision of DGLA may shift eicosanoid production away from pro-inflammatory mediators, theoretically benefiting diseases like rheumatoid arthritis or multiple sclerosis. However, high-quality clinical trials in humans are sparse, and results have been mixed or inconclusive regarding clinical efficacy. Most human studies use GLA-rich oils (e.g., evening primrose oil, borage oil), which rely on endogenous conversion to DGLA, and often focus on surrogate inflammatory markers rather than robust clinical endpoints. Therefore, while the rationale is grounded in biochemistry and some preliminary data, the overall strength of evidence for DGLA’s use in autoimmune disorders is weak to moderate, meriting a rating of 2 out of 5.

More about Dihomo-gamma-linolenic acid
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by Dihomo-gamma-linolenic acid

Products containing Dihomo-gamma-linolenic acid